tbuckley/cabot-search huggingface dataset:
Re-Induction Outcome for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Therapeutic Advances in Childhood Leukemia Consortium
Authors: Weili Sun, Jemily Malvar, Richard Sposto, Anupam Verma, Jennifer J. Wilkes, Robyn M. Dennis, Kenneth Matthew Heym, Elena Eckroth, Jeannette Vandergiesse, Paul S. Gaynon, Alan S. Wayne, James A. Whitlock
Journal: Blood (2015)
Folic Acid for the Prevention of Neural Tube Defects
Authors: Laura E. Mitchell
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Dissection sous muqueuse de lésions caecales à proximité de l’orifice appendiculaire
Journal: Endoscopy (2016)

La dissection sous-muqueuse (DSM) est une technique essentielle dans le traitement des polypes coliques. Mais, la localisation caecale, en particulier au niveau de la valvule, mais aussi à proximité de l’orifice appendiculaire est souvent problématique.
Antifungal Prophylaxis with Oral and Intravenous Itraconazole in Pediatric Stem Cell Tansplantation: A Retrospective Comparison with Fluconazole and Amphotericin B-Preparations in 116 Children.
Authors: Lorenz Grigull, Oliver Kuehlke, Andreas Beilken, Hansjoerg Schmid, Christin Linderkamp, Martin G. Sauer, Klaus Rehe, Karl Welte, Karl W. Sykora
Journal: Blood (2005)
Alternatives in the Evaluation of Suspected Coronary Heart Disease—Reply
Authors: John P. Greenwood, Julia M. Brown, Colin Berry
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P09.07 IDH1 in lower grade oligodendrogliomas: a retrospective study
Authors: A. Innocenti
Journal: Neuro-Oncology (2016)

AbstractIntroduction:In recent years molecular markers have changed the approach to Central Nervous System tumors, showing the inaccuracy of a purely histological classification. Among the markers, mutation of IDH1, an enzyme that modifies DNA methylation allowing the oxidative decarboxylation of isocitrate to 2-oxoglutarate, is a favorable prognostic factor for high and low grade gliomas. IDH1 is rarely mutated in primary glioblastomas, while it is almost constantly mutated in oligodendrogliomas and oligoastrocytomas.Materials and Methods:We retrospectively analyzed 126 patients evaluated at our institution from 2013 to 2015 and with a grade II/III oligodendroglioma or oligoastrocytoma. 37 patients without mutation of IDH1 (IDH1 wild type or IDH1wt) were selected. Recurrence rate, PFS and the OS were analyzed; a comparison with IDH1 mutated tumors have been made.Results:Patients with IDH1wt have a recurrence rate higher than those with IDH1 mutation. They also have both an OS and a PFS shorter. Among the 37 patients with IDH1wt, 8 have 1p/19q codeletion.Conclusions:Patients with IDH1wt grade II/III glioma with oligodendroglial component have a worse prognosis than patients with mutated IDH1. They have an evolution resembling that of grade IV tumors. Interestingly, a small group of IDH1wt tumors unusually have 1p/19q co-deletion; asserting that all gliomas with 1p/19q codeletion are IDH1 mutated is a simplification. We believe that WHO classification should take into account molecular data in addition to histological ones. A molecular classification in the future may provide a targeted therapy for patients.
Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Christoph Schliemann, Katrin Gutbrodt, Andrea Kerkhoff, Michele Pohlen, Stefanie Wiebe, Gerda Silling, Linus Angenendt, Torsten Kessler, Rolf M Mesters, Leonardo Giovannoni, Michael Schäfers, Bianca Altvater, Claudia Rössig, Inga Grünewald, Eva Wardelmann, Gabriele Köhler, Dario Neri, Matthias Stelljes, Wolfgang E Berdel
Journal: Blood (2014)
Efficacy and Toxicity of FLAI-G-CSF and Mylotarg for Induction/Consolidation of AML Patients, Not Treatable with Conventional Chemotherapy.
Authors: Michele Malagola, Michela Rondoni, Domenico Russo, Pier Paolo Piccaluga, Stefania Paolini, Costanza Bosi, Stavroula Gaitani, Giuseppe Visani, Giovanni Martinelli, Michele Baccarani
Journal: Blood (2004)
Successful and Safe Treatment of Canine Hemophilia by Continuous Expression of Canine FVIIa: a Model for FVIII/FIX Gene-Based Bypassing Agents
Authors: Paris Margaritis, Elise Roy, Majed N Aljamali, Harre Downey, Shangzhen Zhou, Elizabeth Merricks, Aaron Dillow, Timothy C Nichols, Katherine A. High
Journal: Blood (2008)
Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia
Authors: David O’Connor, Anthony V. Moorman, Rachel Wade, Jeremy Hancock, Ronald M.R. Tan, Jack Bartram, John Moppett, Claire Schwab, Katharine Patrick, Christine J. Harrison, Rachael Hough, Nick Goulden, Ajay Vora, Sujith Samarasinghe
Journal: Journal of Clinical Oncology (2017)

Purpose Our aim was to determine the role of end-of-induction (EOI) minimal residual disease (MRD) assessment in the identification and stratification of induction failure in patients with pediatric acute lymphoblastic leukemia (ALL) and to identify genetic abnormalities that drive disease in these patients. Patients and Methods Analysis included 3,113 patients who were treated in the Medical Research Council UKALL2003 multicenter randomized trial (NCT00222612) between 2003 and 2011. MRD was measured by using standardized real-time quantitative PCR. Median follow-up was 5 years 9 months. Results Fifty-nine patients (1.9%) had morphologic induction failure with 5-year event-free survival (EFS) of 50.7% (95% CI, 37.4 to 64.0) and 5-year overall survival of 57.7% (95% CI, 44.2 to 71.2). Of these, a small proportion of patients with M2 marrow (6 of 44) and a low EOI MRD level (< 0.01%) had 5-year EFS of 100%. Conversely, among patients with morphologic remission 2.3% (61 of 2,633) had high MRD (≥ 5%) and 5-year EFS of 47.0% (95% CI, 32.9 to 61.1), which was similar to those with morphologic induction failure. Redefining induction failure to include morphologic induction failure and/or MRD ≥ 5% identified 3.9% (120 of 3,133 patients) of the trial cohort with 5-year EFS of 48.0% (95% CI, 39.3 to 58.6). Induction failure (morphologic or MRD ≥ 5%) occurred most frequently in T-ALL (10.1%; 39 of 386 T-ALL cases) and B-other ALL, that is, lacking established chromosomal abnormalities (5.6%; 43 of 772 B-other cases). Genetic testing within the B-other group revealed the presence of PDGFRB gene fusions, particularly EBF1-PDGFRB, in almost one third of B-other ALL cases. Conclusion Integration of EOI MRD level with morphology identifies induction failure more precisely than morphology alone. Prevalence of EBF1-PDGFRB fusions in this group highlights the importance of genetic screening to identify abnormalities that may be targets for novel agents.
Non–myeloablative Allogeneic Hematopoietic Stem Cell Transplantation with Low-Dose Total Body Irradiation and Peri-Transplant Rituximab for B Cell Non-Hodgkin Lymphoma: Favorable Disease Control in Chemosensitive Patients,
Authors: Craig S Sauter, Esperanza B Papadopoulos, Miguel-Angel Perales, Ann A Jakubowski, Jenna D Goldberg, Guenther Koehne, Lauren Lechner, Craig H. Moskowitz, Sergio Giralt, Juliet N Barker, Hugo Castro-Malaspina
Journal: Blood (2011)
Increased Type I Interferon Signaling and Inflammatory Factors Associated with T-Bet+ Cytotoxic Effectors in Chronic Graft Versus Host Disease of Oral Mucosa.
Authors: Mati n M. Imanguli, William D. Swaim, Stacy League, Ronald E. Gress, Steven Z. Pavletic, Frances T. Hakim
Journal: Blood (2008)
TCT-614 Patient-specific Coronary Stenoses Can Be Modeled Using a Combination of Optical Coherence Tomography and Flow Velocities to Accurately Predict Hyperaemic Pressure Gradients
Authors: Chrysa A. Kousera, Sukhjinder S. Nijjer, Ryo Torii, Ricardo Petraco, Sayan Sen, Nicolas Foin, Christopher Broyd, Alun D. Hughes, Yun X. Xu, Darrel P. Francis, Justin E. Davies
Journal: Journal of the American College of Cardiology (2013)
Prospective study of electrical impedance scanning for identifying young women at risk for breast cancer
Authors: A. Stojadinovic, O. Moskovitz, Z. Gallimidi, S. Fields, A. D. Brooks, R. Brem, R. N. Mucciola, M. Singh, C. D. Shriver
Journal: Journal of Clinical Oncology (2005)

692 Background: One way to improve cost-benefit for breast cancer screening in younger women is to identify those at high-risk of breast cancer and manage these women in an optimal manner. The purpose of this study is to evaluate the sensitivity and specificity of Electrical Impedance Scanning (EIS) for identifying young women who are at-risk for having breast cancer and should be followed up with advanced imaging technologies. Methods: A prospective observational two-arm multi-site clinical trial was performed on women aged 30–45 years. Exclusion criteria included: age <30 or >45, pregnancy, current cancer treatment, recent breast surgery or biopsy, or implanted electrical device. The “Sensitivity arm” included Clinical Breast Examination (CBE) and EIS on 189 women prior to breast biopsy. The “Specificity arm” included 1,361 asymptomatic women undergoing annual well-woman examination and EIS. Primary endpoints included EIS sensitivity, specificity and risk identifying capability. Relative risk of cancer with a positive EIS was computed and compared with other approaches commonly used to define “high-risk” in this population. Potential covariates (age, menopausal status, hormone use, family history, breast cup size, palpability) were analyzed using logistic regression to assess effect on sensitivity or specificity. Results: Fifty of 189 women in the Sensitivity arm had verified cancers, 19 of whom had positive EIS examination resulting in sensitivity of 38% (19/50; 95% CI, 25%–50%). Sensitivity is higher for T1(<2cm) than T2(2–5cm)[50% vs. 19%;P=0.048]. Of the1361 women in the Specificity arm, 67 had positive EIS examination resulting in a specificity of 95% (1294/1361; 95% CI, 94%–96%). EIS specificity was significantly correlated with breast cup size (P =0.01). The relative risk of a woman with a positive EIS examination was 7.68, which compares favorably with other established lifetime breast cancer risk identifiers (e.g. two affected first-degree relatives or atypical ductal hyperplasia). Conclusions: EIS may have an important role as a screening tool for identifying at-risk young women who should be followed more closely with advanced imaging technologies for early detection of breast cancer. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Mirabel Medical
Ex-Vivo Expanded Human Bone Marrow-Derived AC133+ Cells To Treat Myocardial Infarction.
Authors: Frida Grynspan, Moshe Marikovsky, Efrat Landau, Tony Peled, Arnon Nagler, Radka Holbova, Victor Guetta, Shmuel Fuchs, Shimon Feinberg, Jonathan Leor
Journal: Blood (2004)
TIMING AND MODE OF DELIVERY IN PRENATALLY DIAGNOSED CRITICAL CONGENITAL HEART DISEASE: AN ANALYSIS OF PRACTICES WITHIN THE UNIVERSITY OF CALIFORNIA FETAL CONSORTIUM
Authors: Shabnam Peyvandi, Tina A. Nguyen, Tracy Anton, Nina M. Boe, Laila Rhee-Morris, Mark Sklansky, Maryam Tarsa, Anita Moon-Grady
Journal: Journal of the American College of Cardiology (2014)
Clinical Features of Shwachman-Diamond Syndrome Patients Lacking Biallelic SBDS Mutation
Authors: Akiko Shimamura, Audrey Anna Bolyard, Satabdi Chakrabarti, Jordan M. Bond, Theresa Cole, Joan Moore, Laurence A. Boxer, Peter E. Newburger, Blanche P Alter, Richard E. Harris, Stella M. Davies, David C. Dale
Journal: Blood (2011)
Male breast cancer: Combined modality therapy improves survival
Authors: S. Fogh, A. Hirsch, S. Goldberg, S. Powell, L. Kachnic
Journal: Journal of Clinical Oncology (2005)

873 Background Male breast cancer accounts for 1% of all reported breast cancer cases. Due to its rarity, there are no large datasets examining the impact of adjuvant therapy. The purpose of this study is to assess survival in male patients with non-metastatic breast cancer who received surgery (S) with or without adjuvant therapy (Tamoxifen [T], chemotherapy [CT], and/or radiation [RT]). Methods A retrospective analysis of all male breast cancer patients receiving therapy at the Massachusetts General Hospital and Boston Medical Center between 1990 and 2003 was performed. Factors recorded included age, ER/PR status, tumor histology, stage (AJCC), and details of local and systemic treatment. Five and ten-year DFS and OS were calculated from the date of pathological diagnosis using the actuarial Kaplan-Meier method with comparisons made using the log-rank test. Results Forty-two men received treatment for localized breast cancer. Median age: 61 years (24–90). S: mastectomy in 34 and lumpectomy in 8. Thirty-four (80%) presented with infiltrating ductal pathology. All tumors were ER positive; 95% PR positive. Tumor stage was Tis in 3, 12 stage I, 23 stage II, 3 stage III and 1 unknown. Eleven received postoperative RT and 18 received CT. Fifteen received T in addition to CT and/or RT, and 6 received T alone. Median follow-up: 3.9 years (1–11). Survival data is reported in tabular format. Ten-year DFS and OS rates are superior in the 9 patients who received both T and RT as adjuvant management (100% and 100% respectively). Conclusions This series emphasizes the important role of adjuvant Tamoxifen and RT in the management of localized male breast cancer. No significant financial relationships to disclose.
Mortality and Morbidities During Long-Term Follow-up After Recovery From Thrombotic Thrombocytopenic Purpura (TTP)
Authors: Jessica A. Reese, Zayd L. Al-Nouri, Cassandra C. Deford, Lauren M. Stewart, Deirdra R. Terrell, Sara K. Vesely, Johanna A. Kremer Hovinga, Bernhard Lämmle, James N. George
Journal: Blood (2012)
Acute Gvhd Is a Strong Predictor of Full Donor cd3+ t Cells Chimerism (TCC) After Reduced Intensity Conditioning (RIC) for Allogeneic Stem Cell Transplantation (Allo-SCT)
Authors: Jean El-Cheikh, Alberto Vazquez, Roberto Crocchiolo, Sabine Furst, Luca Castagna, Catherine Faucher, Claire Oudin, Boris Calmels, Angela Granata, Jean-François Eliaou, Didier Blaise
Journal: Blood (2011)
RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells
Authors: Xiaowei Wei, Yong Xu, Fang Fang Xu, Luksana Chaiswing, David Schnell, Teresa Noel, Chi Wang, Jinfei Chen, Daret K. St. Clair, William H. St. Clair
Journal: Cancer Research (2017)

Cancer cells typically experience higher oxidative stress than normal cells, such that elevating pro-oxidant levels can trigger cancer cell death. Although pre-exposure to mild oxidative agents will sensitize cancer cells to radiation, this pre-exposure may also activate the adaptive stress defense system in normal cells. Ascorbic acid is a prototype redox modulator that when infused intravenously appears to kill cancers without injury to normal tissues; however, the mechanisms involved remain elusive. In this study, we show how ascorbic acid kills cancer cells and sensitizes prostate cancer to radiation therapy while also conferring protection upon normal prostate epithelial cells against radiation-induced injury. We found that the NF-κB transcription factor RelB is a pivotal determinant in the differential radiosensitization effects of ascorbic acid in prostate cancer cells and normal prostate epithelial cells. Mechanistically, high reactive oxygen species concentrations suppress RelB in cancer cells. RelB suppression decreases expression of the sirtuin SIRT3 and the powerful antioxidant MnSOD, which in turn increases oxidative and metabolic stresses in prostate cancer cells. In contrast, ascorbic acid enhances RelB expression in normal cells, improving antioxidant and metabolic defenses against radiation injury. In addition to showing how RelB mediates the differential effects of ascorbic acid on cancer and normal tissue radiosensitivities, our work also provides a proof of concept for the existence of redox modulators that can improve the efficacy of radiotherapy while protecting against normal tissue injury in cancer settings. Cancer Res; 77(6); 1345-56. ©2017 AACR.
Treatment with Histone Deacetylase 6-Specific Inhibitor WT-161 Disrupts hsp90 Function, Abrogates Aggresome Formation and Sensitizes Human Mantle Cell Lymphoma Cells to Lethal ER Stress Induced by Proteasome Inhibitor Carfilzomib
Authors: Rekha Rao, Warren Fiskus, Ramesh Balusu, Hongwei Ma, James Bradner, Jianguo Tao, Eduardo M. Sotomayor, Kapil N. Bhalla
Journal: Blood (2010)
Phase I, Multicenter, Open Label, Dose Escalation of 90yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma
Authors: Christos Vaklavas, Ruby F Meredith, Susan J. Knox, Gregory Wiseman, Thomas E. Witzig, Ivana N. Micallef, Albert F. Lobuglio, Andres Forero
Journal: Blood (2011)
Rig-G Protein Links Retinoid and Interferon Signal Pathways To Inhibit Cell Cycle through Increased p27 and p21 Protein Levels.
Authors: Jian-Hua Tong, Shu Xiao, Dong Li, Hai-Qing Zhu, Man-Gen Song, Pei-Min Jia, Xiao-Rong Pan, Sai-Juan Chen, Zhu Chen
Journal: Blood (2006)
Comparison of the Efficacy of Placebo and Best Available Therapy for the Treatment of Myelofibrosis in the COMFORT Studies
Authors: Ruben A. Mesa, Srdan Verstovsek, Francisco Cervantes, Roger J. Waltzman, Estella T. Mendelson, Nicolas Martin, William Sun, Victor A. Sandor, Richard S. Levy, Claire N. Harrison
Journal: Blood (2011)
EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression
Authors: Davide Pradella, Chiara Naro, Claudio Sette, Claudia Ghigna
Journal: Molecular Cancer (2017)

Epithelial-to-mesenchymal transition (EMT) is associated with metastasis formation as well as with generation and maintenance of cancer stem cells. In this way, EMT contributes to tumor invasion, heterogeneity and chemoresistance. Morphological and functional changes involved in these processes require robust reprogramming of gene expression, which is only partially accomplished at the transcriptional level. Alternative splicing is another essential layer of gene expression regulation that expands the cell proteome. This step in post-transcriptional regulation of gene expression tightly controls cell identity between epithelial and mesenchymal states and during stem cell differentiation. Importantly, dysregulation of splicing factor function and cancer-specific splicing isoform expression frequently occurs in human tumors, suggesting the importance of alternative splicing regulation for cancer biology. In this review, we briefly discuss the role of EMT programs in development, stem cell differentiation and cancer progression. Next, we focus on selected examples of key factors involved in EMT and stem cell differentiation that are regulated post-transcriptionally through alternative splicing mechanisms. Lastly, we describe relevant oncogenic splice-variants that directly orchestrate cancer stem cell biology and tumor EMT, which may be envisioned as novel targets for therapeutic intervention.
A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies.
Authors: Ian W. Flinn, Marshall T. Schreeder, Nina Wagner-Johnston, Ralph V. Boccia, John P. Leonard, Steven E. Coutre, Leanne M. Holes, Sissy Peterman, Albert S. Yu
Journal: Blood (2010)
Dexamethasone Induces Apoptosis “Ex Vivo” in Chronic Lymphocytic Leukemia Cells with Either Unmutated IgVH Genes or High ZAP-70 Expression.
Authors: Ana Muntanola, Marta Crespo, Eva Gine, Neus Villamor, Emili Montserrat, Francesc Bosch
Journal: Blood (2005)
Different Definitions of Progression-Free Survival (PFS) and Event-Free Survival (EFS) May Result In Perceived but Not Real Differences In Long-Term Outcome When Comparing Trials In Chronic Myeloid Leukemia (CML)
Authors: Hagop Kantarjian, Susan O'Brien, Elias Jabbour, Jianqin Shan, Farhad Ravandi, Tapan Kadia, Jorge E. Cortes, Stefan Faderl, Guillermo Garcia-Manero, Gautam Borthakur
Journal: Blood (2010)
Discontinuous Epitopes On FVIII A2 Domain Mapped by Computer-Designed Synthetic Peptides
Authors: Aurélien Lebreton, Noémie Simon, Violaine Moreau, Vincent Demolombe, Christopher Cayzac, Christophe Nguyen, Priscilla Lapalud, Daniel Laune, Jean-François Schved, Claude Granier, Géraldine Lavigne
Journal: Blood (2012)
Novel Agents and Autologous Stem Cell Transplantation Improve Survival of Multiple Myeloma Patients with Ages 65–70 Years: A Multicenter Retrospective Collaborative Study Between Japanese Society of Myeloma and European Myeloma Network
Authors: Shuji Ozaki, Takeshi Harada, Takayuki Saitoh, Chihiro Shimazaki, Mitsuhiro Itagaki, Hideki Asaoku, Yoshiaki Kuroda, Takaaki Chou, Yumiko Yoshiki, Kenshi Suzuki, Hirokazu Murakami, Kunihiko Hayashi, Antonio Palumbo, Kazuyuki Shimizu
Journal: Blood (2012)
Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)
Authors: Ravi Vij, Michael Wang, Robert Orlowski, A. Keith Stewart, Sundar Jagannath, Vishal Kukreti, Jessica Taylor, Diana Fuhrman, Scott Cruickshank, Richard Schwartz, Lori Kunkel, David Siegel
Journal: Blood (2008)
Midostaurin a Multi-Targeted Oral Kinase Inhibitor in Systemic Mastocytosis: Report of An Open-Label Compassionate Use Program in the United Kingdom
Authors: Steven Knapper, Jonathan Cullis, Mark W. Drummond, Roger Evely, Tamara Everington, Christine Hoyle, Lorna McLintock, Christopher Poynton, Deepti Radia
Journal: Blood (2011)
The BH3 Mimetic, ABT-737, Overcomes Stromal-Mediated Pro-Survival Signals and Synergizes with PHA-767491, a Dual Cdc7/CDK9 Inhibitor, In Acute Myeloid Leukaemia
Authors: Ruth C Morrell, Eva Szegezdi, Anna Halpin-McCormick, Karen Cawley, Afshin Samali, Michael O'Dwyer
Journal: Blood (2010)